Hyder Salman M, Liang Yayun, Wu Jianbo
Department of Biomedical Sciences, University of Missouri, Columbia, 65211, USA.
Int J Cancer. 2009 Sep 1;125(5):1045-53. doi: 10.1002/ijc.24373.
Expression of thrombospondin-1 (TSP-1), a large extracellular matrix protein, has been associated with modulation of angiogenesis and tumor growth. Both pro and antiangiogenic properties of TSP-1 have been described, and the role of TSP-1 expression in the growth and progression of human breast cancer is not clear. Because estrogens cause progression of many breast cancers, and estradiol (E2) downregulates a TSP-1 receptor, we examined whether TSP-1 is regulated by estrogen and involved in tumor progression. E2 induced TSP-1 expression in T47-D and MCF-7 breast cancer cells in vitro within 3 to 6 hr; the induction was blocked by the anti-estrogen ICI 182,780, indicating that estrogen receptors (ER) are necessary for this effect. Furthermore, E2 caused the production of TSP-1 protein from tumor cells in an ER-alpha-dependent manner. The E2-mediated TSP-1 RNA induction was dose-dependent and blocked by actinomycin D, indicating that the response to E2 was at least partly transcriptional. Transfection studies with deletion constructs of the TSP-1 promoter identified an estrogen-responsive region in the human TSP-1 promoter, located between -2,200 and -1,792 bp upstream of the transcription start site. An antibody against TSP-1 restricted the proliferation of E2-dependent MCF-7 cells in vitro and in vivo. A panel of breast cancer cells proliferated in the presence of low concentrations of exogenous TSP-1, whereas higher concentrations inhibited proliferation. A real-time PCR analysis showed that E2 also induced TSP-1 mRNA in the normal mammary glands of immature ovariectomized mice in an ER-dependent manner. In summary, we report the novel observation that TSP-1 production is directly controlled by estrogens in ER-positive breast cancer cells, and the released protein has pro-growth regulatory functions. Consequently, we propose that TSP-1 could be a therapeutic target for anti-tumor therapy in early-stage tumors. (c) 2009 UICC.
血小板反应蛋白-1(TSP-1)是一种大型细胞外基质蛋白,其表达与血管生成调节及肿瘤生长有关。TSP-1的促血管生成和抗血管生成特性均有报道,而TSP-1表达在人类乳腺癌生长和进展中的作用尚不清楚。由于雌激素会导致许多乳腺癌进展,且雌二醇(E2)会下调一种TSP-1受体,我们研究了TSP-1是否受雌激素调节并参与肿瘤进展。E2在体外3至6小时内诱导T47-D和MCF-7乳腺癌细胞中TSP-1表达;该诱导作用被抗雌激素药物ICI 182,780阻断,表明雌激素受体(ER)对于此效应是必需的。此外,E2以依赖ER-α的方式促使肿瘤细胞产生TSP-蛋白。E2介导的TSP-1 RNA诱导呈剂量依赖性,并被放线菌素D阻断,表明对E2的反应至少部分是转录性的。用TSP-1启动子缺失构建体进行的转染研究在人类TSP-1启动子中确定了一个雌激素反应区域,位于转录起始位点上游-2200至-1792 bp之间。抗TSP-1抗体在体外和体内均限制了依赖E2的MCF-7细胞的增殖。一组乳腺癌细胞在低浓度外源性TSP-1存在下增殖,而较高浓度则抑制增殖。实时PCR分析表明,E2也以依赖ER的方式在未成熟去卵巢小鼠的正常乳腺中诱导TSP-1 mRNA表达。总之,我们报告了一项新发现,即TSP-1的产生在ER阳性乳腺癌细胞中直接受雌激素控制,且释放的蛋白具有促生长调节功能。因此,我们提出TSP-1可能是早期肿瘤抗肿瘤治疗的一个治疗靶点。(c)2009 UICC。